StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) shareholders

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)

Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
44M of 40M shares
Institutional holders
253
38 new, 24 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 15 sales
Net sold $2.39M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
BlackRock, Inc.7,017,11915.20%13G (passive) amendmentMar 31, 2025
Joe M. Thomson
Joint filing with Pacer Advisors, Inc. (6.93%), Pacer US Small Cap Cash Cows ETF (6.92%)
3,262,8376.93%13G (passive)Dec 31, 2024
Pedro Escudero
Joint filing with Doma Perpetual Capital Management LLC (6.90%), Doma1 LLC (6.90%)
2,936,7947.30%13D (active) amendmentMar 11, 2026
Doma2 LLC
Joint filing with Doma Perpetual Capital Management LLC (6.83%), DOMA Perpetual LO Equity Master Fund LP (6.83%) and 2 more
2,936,7946.83%13D (active) amendmentNov 6, 2025
Vanguard Portfolio Management2,585,9646.38%13G (passive)Mar 31, 2026
Renaissance Technologies LLC
Joint filing with Renaissance Technologies Holdings Corporation (5.34%)
2,395,6015.34%13G (passive)Apr 8, 2025
Israel A. Englander
Joint filing with Millennium Management LLC (5.10%), Millennium Group Management LLC (5.10%)
2,338,3695.10%13G (passive)Jan 10, 2025
Dimensional Fund Advisors LP2,060,5975.10%13G (passive)Mar 31, 2026
State Street Corporation2,059,9775.20%13G (passive)Jun 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of PCRXValueChange% of portfolio
BlackRock, Inc.6,705,80916.82%$170.13M−29,5340.00%
Doma Perpetual Capital Management LLC2,777,7946.97%$70.47M–16.36%
Vanguard Portfolio Management LLC2,406,2386.04%$61.05M−95,0480.00%
Dimensional Fund Advisors LP2,103,2455.28%$53.36M+42,6480.01%
State Street Corp2,059,9775.17%$52.26M+140,3670.00%
D. E. Shaw & Co., Inc.1,950,3324.89%$49.48M−32,3920.02%
Renaissance Technologies LLC1,733,8014.35%$43.99M−91,7000.06%
Vanguard Capital Management LLC1,691,5714.24%$42.92M−92,4780.00%
Goldman Sachs Group Inc1,527,1293.83%$38.74M−42,7870.00%
Geode Capital Management, LLC1,158,6932.91%$29.40M+14,8730.00%
Morgan Stanley1,144,6542.87%$29.04M−247,8940.00%
American Century Companies Inc1,018,0932.55%$25.83M+180,5300.01%
UBS Group AG920,2172.31%$23.35M+358,1770.00%
Impax Asset Management Group plc750,0271.88%$19.03M–0.12%
Two Sigma Investments, LP724,6041.82%$18.38M+197,7530.01%
Charles Schwab Investment Management Inc690,7861.73%$17.53M−41,2560.00%
Gagnon Securities LLC608,6171.53%$15.44M−8,8932.98%
Lsv Asset Management608,3761.53%$15.43M+91,2760.03%
Wellington Management Group Llp563,4581.41%$14.29M+85,0750.00%
Northern Trust Corp526,7821.32%$13.36M+7,3700.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202625344M100.0%38 / 8284 / 243M3M
Q1 202624244M100.0%29 / 9085 / 437M6M
Q4 202526147M100.0%49 / 8792 / 245M6M
Q3 202523948M100.0%37 / 6696 / 305M7M
Q2 202523351M100.0%31 / 8477 / 326M6M
Q1 202523551M100.0%35 / 8477 / 3110M9M
Q4 202423350M100.0%36 / 7780 / 408M10M
Q3 202423952M100.0%47 / 8868 / 8824M16M
Q2 202428253M100.0%51 / 10676 / 388M6M
Q1 202427151M100.0%38 / 9983 / 286M4M
Q4 202326149M100.0%41 / 8891 / 387M5M
Q3 202326147M100.0%41 / 9687 / 385M5M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

291 funds held PCRX in Q2 2026, 60% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of PCRXValue% of fundAs of
iShares Core S&P Small-Cap ETF2,371,1275.95%$60.16M0.05%Jun 30, 2026
Vanguard Total Stock Market Index Fund1,198,7923.01%$30.41M0.00%Jun 30, 2026
iShares Russell 2000 ETF1,033,7882.59%$26.23M0.03%Jun 30, 2026
Vanguard Small-Cap Index Fund856,2132.15%$21.72M0.01%Jun 30, 2026
Avantis U.S. Small Cap Value ETF762,5061.91%$17.71M0.07%May 31, 2026
Impax Small Cap Fund750,0271.88%$19.03M2.00%Jun 30, 2026
U.S. Small Cap Value Portfolio570,1771.43%$15.06M0.08%Jul 31, 2026
Vanguard Small-Cap Value Index Fund542,8761.36%$13.77M0.02%Jun 30, 2026
Vanguard Extended Market Index Fund453,7541.14%$11.51M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund432,5051.09%$11.42M0.03%Jul 31, 2026
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF360,6320.90%$9.15M0.05%Jun 30, 2026
iShares S&P Small-Cap 600 Growth ETF351,9410.88%$8.93M0.11%Jun 30, 2026
DWS Small Cap Core Fund349,9060.88%$8.88M0.77%Jun 30, 2026
iShares Russell 2000 Value ETF340,1700.85%$8.63M0.06%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF279,1520.70%$7.08M1.65%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Frank D. LeeChief Executive Officer, Director0–Nov 17, 2026
Jonathan SloninChief Medical Officer0–Nov 17, 2026
Shawn CrossChief Financial Officer0–Nov 17, 2026
Kristen WilliamsChief Administrative Officer0–Nov 17, 2026
Brendan TeehanChief Commercial Officer0–Nov 17, 2026
Lauren RikerSenior Vice President, Finance0–Nov 17, 2026
Daryl GauglerChief Operating Officer115,4430.29%Jan 6, 2025
Marcelo BigalDirector0–Nov 17, 2026
Michael J. YangDirector0–Nov 17, 2026
Thomas G. WiggansDirector––Nov 17, 2026
Laura BregeDirector0–Nov 17, 2026
Mark FroimsonDirector0–Nov 17, 2026
Christopher ChristieDirector0–Nov 17, 2026
Samit HirawatDirector0–Nov 17, 2026
Alethia YoungDirector0–Nov 17, 2026
Mark A. KronenfeldDirector31,0650.08%Mar 19, 2026
Abraham CeesayDirector9,0390.02%Sep 8, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Frank D. Lee
Chief Executive Officer, Director
Nov 17, 2026Returned to company−660,830.841$36.50$24.12M0
Alethia Young
Director
Nov 17, 2026Returned to company−17,798$36.50$649.63K0
Samit Hirawat
Director
Nov 17, 2026Returned to company−6,405$36.50$233.78K0
Michael J. Yang
Director
Nov 17, 2026Returned to company−6,405$36.50$233.78K0
Michael J. Yang
Director
Nov 17, 2026Tender of shares−13,393$36.50$488.84K6,405
Kristen Williams
Chief Administrative Officer
Nov 17, 2026Returned to company−167,062$36.50$6.10M0
Brendan Teehan
Chief Commercial Officer
Nov 17, 2026Returned to company−100,934.268$36.50$3.68M0
Christopher Christie
Director
Nov 17, 2026Returned to company−6,405$36.50$233.78K0
Christopher Christie
Director
Nov 17, 2026Tender of shares−16,654$36.50$607.87K6,405
Shawn Cross
Chief Financial Officer
Nov 17, 2026Returned to company−86,591$36.50$3.16M0
Shawn Cross
Chief Financial Officer
Nov 17, 2026Tender of shares−9,210$36.50$336.17K86,591
Mark Froimson
Director
Nov 17, 2026Returned to company−6,405$36.50$233.78K0
Mark Froimson
Director
Nov 17, 2026Tender of shares−20,136$36.50$734.96K6,405
Marcelo Bigal
Director
Nov 17, 2026Returned to company−6,405$36.50$233.78K0
Marcelo Bigal
Director
Nov 17, 2026Tender of shares−11,393$36.50$415.84K6,405
Lauren Riker
Senior Vice President, Finance
Nov 17, 2026Returned to company−55,403$36.50$2.02M0
Lauren Riker
Senior Vice President, Finance
Nov 17, 2026Tender of shares−6,881.242$36.50$251.17K55,403
Laura Brege
Director
Nov 17, 2026Returned to company−6,405$36.50$233.78K0
Laura Brege
Director
Nov 17, 2026Tender of shares−23,715$36.50$865.60K6,405
Jonathan Slonin
Chief Medical Officer
Nov 17, 2026Returned to company−216,729.67$36.50$7.91M0
Shawn Cross
Chief Financial Officer
Oct 30, 2026Tax withholding−9,540$36.39$347.16K95,801
Lauren Riker
Senior Vice President, Finance
Oct 8, 2026Sale(10b5-1 plan)−6,000$36.32$217.92K62,284
Lauren Riker
Senior Vice President, Finance
Oct 8, 2026Option exercise+6,000$32.35$194.10K68,284
Jonathan Slonin
Chief Medical Officer
Aug 17, 2026Sale(10b5-1 plan)−3,040$23.23$70.62K216,384
Lauren Riker
Senior Vice President, Finance
Jun 11, 2026Sale(10b5-1 plan)−6,115$23.50$143.70K62,284
Christopher Christie
Director
Jun 10, 2026Award+6,405––23,059
Michael J. Yang
Director
Jun 10, 2026Award+6,405––19,798
Samit Hirawat
Director
Jun 10, 2026Award+6,405––6,405
Laura Brege
Director
Jun 10, 2026Award+6,405––30,120
Alethia Young
Director
Jun 10, 2026Award+6,405––17,798
Mark Froimson
Director
Jun 10, 2026Award+6,405––26,541
Marcelo Bigal
Director
Jun 10, 2026Award+6,405––17,798
Kristen Williams
Chief Administrative Officer
Jun 4, 2026Sale(10b5-1 plan)−10,259$22.27$228.47K167,062
Kristen Williams
Chief Administrative Officer
Jun 3, 2026Tax withholding−8,528$22.32$190.34K177,321
Jonathan Slonin
Chief Medical Officer
Jun 3, 2026Tax withholding−4,728$22.32$105.53K218,912
Lauren Riker
Senior Vice President, Finance
Jun 3, 2026Tax withholding−3,187$22.32$71.13K68,399
Shawn Cross
Chief Financial Officer
Apr 23, 2026Sale(10b5-1 plan)−12,941$25.16$325.60K105,341
Shawn Cross
Chief Financial Officer
Apr 23, 2026Option exercise+12,941$16.45$212.88K118,282
Shawn Cross
Chief Financial Officer
Apr 22, 2026Sale(10b5-1 plan)−1,500$25.01$37.52K105,341
Shawn Cross
Chief Financial Officer
Apr 22, 2026Option exercise+1,500$16.45$24.68K106,841
Shawn Cross
Chief Financial Officer
Apr 21, 2026Sale(10b5-1 plan)−2,845$25.01$71.15K105,341
Shawn Cross
Chief Financial Officer
Apr 21, 2026Option exercise+2,845$16.45$46.80K108,186
Shawn Cross
Chief Financial Officer
Apr 20, 2026Option exercise+7,714$16.45$126.90K113,055
Shawn Cross
Chief Financial Officer
Apr 20, 2026Sale(10b5-1 plan)−7,714$25.14$193.93K105,341
Mark Froimson
Director
Mar 17, 2026Sale−500$21.81$10.91K20,136
Jonathan Slonin
Chief Medical Officer
Mar 17, 2026Sale(10b5-1 plan)−3,261$22.82$74.42K223,640
Shawn Cross
Chief Financial Officer
Feb 11, 2026Award+49,091––105,341
Jonathan Slonin
Chief Medical Officer
Feb 11, 2026Award+54,546––226,901
Brendan Teehan
Chief Commercial Officer
Feb 11, 2026Award+51,714––100,934
Frank D. Lee
Chief Executive Officer, Director
Feb 11, 2026Award+261,818––660,831
Kristen Williams
Chief Administrative Officer
Feb 11, 2026Award+54,546––185,849
Lauren Riker
Senior Vice President, Finance
Feb 11, 2026Award+19,273––71,586
Kristen Williams
Chief Administrative Officer
Feb 2, 2026Sale(10b5-1 plan)−13,137$20.53$269.70K131,303
Lauren Riker
Senior Vice President, Finance
Feb 2, 2026Sale(10b5-1 plan)−4,000$20.81$83.24K52,313
Kristen Williams
Chief Administrative Officer
Jan 30, 2026Tax withholding−17,134$20.54$351.93K144,440
Frank D. Lee
Chief Executive Officer, Director
Jan 30, 2026Tax withholding−41,488$20.54$852.16K399,013
Lauren Riker
Senior Vice President, Finance
Jan 30, 2026Tax withholding−2,751$20.54$56.51K56,313
Jonathan Slonin
Chief Medical Officer
Jan 30, 2026Tax withholding−6,168$20.54$126.69K172,355
Brendan Teehan
Chief Commercial Officer
Jan 30, 2026Tax withholding−5,182$20.54$106.44K49,220
Lauren Riker
Senior Vice President, Finance
Jan 5, 2026Sale(10b5-1 plan)−1,416$24.24$34.32K59,064

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
8.94%
3M shares short
Days to cover
3.9
At 1M shares a day
Change since last report
-21.4%
From 4M shares
Short volume, 20 days
27.9%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Pacira BioSciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 16,029 shares on Oct 9, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Lauren Riker
Officer
Oct 8, 20266,000$217.92KOct 8, 2026Stock Option Exercise
Jonathan Slonin
Officer
Aug 17, 20263,040$70.62KAug 17, 2026ESPP Purchase
Abraham Ceesay
Director
Jun 12, 20269,039$210.37KJun 12, 2026Restricted Stock Vesting
Lauren Riker
Officer
Jun 11, 20266,115$143.70KJun 11, 2026Restricted Stock Vesting
Kristen Williams
Officer
Jun 4, 202610,259$228.47KJun 4, 2026Restricted Stock Vesting
Shawn Cross
Officer
Apr 23, 202612,941$325.58KApr 23, 2026Options Granted - 11/04/2024
Shawn Cross
Officer
Apr 22, 20261,500$37.52KApr 22, 2026Option Granted - 11/04/2024
Shawn Cross
Officer
Apr 21, 20262,845$71.15KApr 21, 2026Option Granted - 11/04/2024
Shawn Cross
Officer
Apr 20, 20267,714$193.91KApr 20, 2026Option Granted 11/04/2024
Jonathan Slonin
Officer
Mar 17, 20263,261$74.42KMar 17, 2026ESPP Purchase
Mark Froimson
Director
Mar 17, 2026500$10.91KMar 17, 2026Restricted Stock Vesting
Kristen Williams
Officer
Feb 2, 202613,137$269.70KFeb 2, 2026Restricted Stock Vesting
Lauren Riker
Officer
Feb 2, 20264,000$84.22KFeb 2, 2026Restricted Stock Vesting
Lauren Riker
Officer
Jan 5, 20261,416$34.32KJan 5, 2026ESPP Purchase
Shawn Cross
Officer
Dec 10, 20259,104$228.91KDec 10, 2025Option Granted 11/04/2024

Congress trades

8 trades in Pacira BioSciences reported by 1 member of the House

MemberTypeTradedAmountFiled
Tom Malinowski
NJ07
BoughtMay 6, 2021$1K–15KJun 23, 2021
48 days late
Tom Malinowski
NJ07
BoughtApr 20, 2021$1K–15KJun 12, 2021
53 days late
Tom Malinowski
NJ07
BoughtJan 15, 2021$1K–15KMar 5, 2021
49 days late
Tom Malinowski
NJ07
BoughtNov 2, 2020$1K–15KMar 5, 2021
123 days late
Tom Malinowski
NJ07
BoughtSep 26, 2019$15KMar 5, 2021
526 days late
Tom Malinowski
NJ07
BoughtAug 23, 2019$1K–15KMar 5, 2021
560 days late
Tom Malinowski
NJ07
BoughtMay 31, 2019$15KMar 5, 2021
644 days late
Tom Malinowski
NJ07
BoughtMay 30, 2019$15KMar 5, 2021
645 days late

See a number that looks wrong?